

From: [Mary Jo Farinella-Evans](#)
To: [AGO - High Cost Prescription Drugs](#)
Cc: [Government Pricing](#)
Subject: Glenmark Pharmaceuticals Inc., USA WAC decrease for Deferasirox
Date: Wednesday, April 1, 2020 10:23:01 AM
Attachments: [image001.png](#)

EXTERNAL SENDER: Do not open attachments or click on links unless you recognize and trust the sender.

Good morning,

Glenmark filed a new drug notice on January 21, 2020 and new drug report on January 23, 2020 for Deferasirox Tablets for Oral Suspension as all three NDCs WAC pricing required notification and reporting under 18 V.S.A. § 4637(b) and § 4637(c). I am now notifying you that effective April 1, 2020, the WAC prices are being decreased on the NDCs as outlined in the chart below. As such, two of the NDCs no longer require reporting per 18 V.S.A. § 4637 guidelines. What is the process for updating the pricing? Thank you.

Products	Strength	NDC	Previous WAC ¹	New WAC ¹ effective April 1,2020
Deferasirox Tablets for Oral Suspension	125 mg	68462049430	\$ 675.89	\$ 190.03
Deferasirox Tablets for Oral Suspension	250 mg	68462049530	\$ 1,351.76	\$ 380.05
Deferasirox Tablets for Oral Suspension	500 mg	68462049630	\$ 2,703.46	\$ 760.08

¹Wholesale Acquisition Cost [WAC] is a list price that does not reflect discounts, chargebacks, rebates, or other price reductions received by wholesalers.

Mary Jo Farinella-Evans

Senior Director Government / Medicaid Compliance, Finance

750 Corporate Drive, Mahwah, NJ 07430, US
(Office) 201-331-4520 | (Mobile) 201-962-6487 | www.glenmarkpharma-us.com

41 years outlined_ FINAL CLIENT-04



DISCLAIMER:

The information contained in this email communication is intended only for the personal and confidential use of the designated recipient named above. This message may be an attorney-client communication, and as such is privileged and confidential. If the reader of this message is not the intended recipient, you are hereby notified that you have received this communication in error, and that any review, dissemination, distribution, or copying of the message is strictly prohibited. If you have received this transmission in error, please destroy this transmission and notify Glenmark Pharmaceuticals Limited immediately by telephone and/or send an email to ithelpdesk@glenmarkpharma.com.